United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $545.80, for a total transaction of $5,185,100.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,111,995.40. This represents a 19.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Stock Down 0.6%

NASDAQ:UTHR traded down $3.09 on Tuesday, reaching $541.83. The stock had a trading volume of 529,056 shares, compared to its average volume of 498,722. The company has a market capitalization of $23.00 billion, a P/E ratio of 20.00, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The stock has a fifty day moving average price of $560.52 and a 200-day moving average price of $526.39.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing the consensus estimate of $7.00 by ($1.18). The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the business posted $6.63 EPS. Sell-side analysts predict that United Therapeutics Corporation will post 26.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on UTHR shares. Bank of America increased their price target on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Morgan Stanley set a $516.00 price objective on United Therapeutics in a research report on Thursday, May 7th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. UBS Group increased their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Finally, Cantor Fitzgerald raised their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research note on Thursday, March 12th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently modified their holdings of the stock. Torren Management LLC bought a new position in United Therapeutics in the 4th quarter valued at $26,000. Activest Wealth Management boosted its stake in shares of United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares during the last quarter. WealthCollab LLC grew its position in shares of United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the period. Rakuten Securities Inc. boosted its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new position in United Therapeutics in the fourth quarter valued at approximately $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.